Real life study of three years omalizumab in patients with difficult-to-control asthma

Even though there are multiple options for the treatment of asthma, there still exists a fair group of patients with difficult-to-control asthma. We describe for the first time the real-world effects of three-year omalizumab treatment on patients with difficult-to-control asthma, seen in a social se...

Full description

Saved in:
Bibliographic Details
Published in:Allergologia et immunopathologia Vol. 43; no. 2; p. 120
Main Authors: López Tiro, J Jesús, Contreras, E Angélica Contreras, del Pozo, M Elena Ramírez, Gómez Vera, J, Larenas Linnemann, D
Format: Journal Article
Language:English
Published: Spain 01.03.2015
Subjects:
Adolescent
Adult
Aged
Anti-Asthmatic Agents - therapeutic use
Asthma - drug therapy
Beclomethasone - therapeutic use
Disease Progression
Emergency Medical Services
Female
Humans
Immunoglobulin E - immunology
Male
Mexico
Middle Aged
Omalizumab - therapeutic use
Respiratory Function Tests
Time Factors
Young Adult
Mexico
Emergency room
Asthmatic crisis
Anti-IgE
Omalizumab
Biological
Difficult-to-control asthma
Severe asthma
Asthma exacerbation
Hospitalisation
ISSN:1578-1267, 1578-1267
Online Access:Get more information
Tags: Add Tag
No Tags, Be the first to tag this record!
Abstract Even though there are multiple options for the treatment of asthma, there still exists a fair group of patients with difficult-to-control asthma. We describe for the first time the real-world effects of three-year omalizumab treatment on patients with difficult-to-control asthma, seen in a social security hospital in a Latin American country. Difficult-to-control asthmatic patients from the out-patient clinic of a regional hospital were recruited to receive a three-year omalizumab course. Efficacy parameters were asthma control test (ACT) score; FEV1; daily beclomethasone maintenance dose; and unplanned visits for asthma exacerbations (emergency room (ER), hospitalisations, intensive care). 52 patients were recruited, 47 completed the three-year treatment (42 female, 15-67 years, mean age 43.5). Comparing efficacy parameters of the year before omalizumab with the 3rd year of omalizumab: mean ACT improved from 12.4 to 20.5, mean FEV1 from 66.3% (standard deviation (SD) 19.1%) to 88.4% (SD 16.2%) of predicted, while mean beclomethasone dose reduced from 1750 to 766 mcg/day and there was a significant reduction in patients experiencing ER visits (from 95% to 19%, p<0.0001), hospitalisation (38% to 2%, p<0.0001) and intensive care (4% to 0, NS). Five patients discontinued omalizumab, two because of an adverse event (anaphylaxis, severe headache, both resolved without sequelae). Omalizumab improved most clinical parameters of Mexican patients with difficult-to-control asthma. Especially the rates of ER visits and hospitalisation were significantly reduced, thus reducing costs. Omalizumab was generally well tolerated.
AbstractList Even though there are multiple options for the treatment of asthma, there still exists a fair group of patients with difficult-to-control asthma. We describe for the first time the real-world effects of three-year omalizumab treatment on patients with difficult-to-control asthma, seen in a social security hospital in a Latin American country. Difficult-to-control asthmatic patients from the out-patient clinic of a regional hospital were recruited to receive a three-year omalizumab course. Efficacy parameters were asthma control test (ACT) score; FEV1; daily beclomethasone maintenance dose; and unplanned visits for asthma exacerbations (emergency room (ER), hospitalisations, intensive care). 52 patients were recruited, 47 completed the three-year treatment (42 female, 15-67 years, mean age 43.5). Comparing efficacy parameters of the year before omalizumab with the 3rd year of omalizumab: mean ACT improved from 12.4 to 20.5, mean FEV1 from 66.3% (standard deviation (SD) 19.1%) to 88.4% (SD 16.2%) of predicted, while mean beclomethasone dose reduced from 1750 to 766 mcg/day and there was a significant reduction in patients experiencing ER visits (from 95% to 19%, p<0.0001), hospitalisation (38% to 2%, p<0.0001) and intensive care (4% to 0, NS). Five patients discontinued omalizumab, two because of an adverse event (anaphylaxis, severe headache, both resolved without sequelae). Omalizumab improved most clinical parameters of Mexican patients with difficult-to-control asthma. Especially the rates of ER visits and hospitalisation were significantly reduced, thus reducing costs. Omalizumab was generally well tolerated.
Even though there are multiple options for the treatment of asthma, there still exists a fair group of patients with difficult-to-control asthma. We describe for the first time the real-world effects of three-year omalizumab treatment on patients with difficult-to-control asthma, seen in a social security hospital in a Latin American country.BACKGROUNDEven though there are multiple options for the treatment of asthma, there still exists a fair group of patients with difficult-to-control asthma. We describe for the first time the real-world effects of three-year omalizumab treatment on patients with difficult-to-control asthma, seen in a social security hospital in a Latin American country.Difficult-to-control asthmatic patients from the out-patient clinic of a regional hospital were recruited to receive a three-year omalizumab course. Efficacy parameters were asthma control test (ACT) score; FEV1; daily beclomethasone maintenance dose; and unplanned visits for asthma exacerbations (emergency room (ER), hospitalisations, intensive care).METHODSDifficult-to-control asthmatic patients from the out-patient clinic of a regional hospital were recruited to receive a three-year omalizumab course. Efficacy parameters were asthma control test (ACT) score; FEV1; daily beclomethasone maintenance dose; and unplanned visits for asthma exacerbations (emergency room (ER), hospitalisations, intensive care).52 patients were recruited, 47 completed the three-year treatment (42 female, 15-67 years, mean age 43.5). Comparing efficacy parameters of the year before omalizumab with the 3rd year of omalizumab: mean ACT improved from 12.4 to 20.5, mean FEV1 from 66.3% (standard deviation (SD) 19.1%) to 88.4% (SD 16.2%) of predicted, while mean beclomethasone dose reduced from 1750 to 766 mcg/day and there was a significant reduction in patients experiencing ER visits (from 95% to 19%, p<0.0001), hospitalisation (38% to 2%, p<0.0001) and intensive care (4% to 0, NS). Five patients discontinued omalizumab, two because of an adverse event (anaphylaxis, severe headache, both resolved without sequelae).RESULTS52 patients were recruited, 47 completed the three-year treatment (42 female, 15-67 years, mean age 43.5). Comparing efficacy parameters of the year before omalizumab with the 3rd year of omalizumab: mean ACT improved from 12.4 to 20.5, mean FEV1 from 66.3% (standard deviation (SD) 19.1%) to 88.4% (SD 16.2%) of predicted, while mean beclomethasone dose reduced from 1750 to 766 mcg/day and there was a significant reduction in patients experiencing ER visits (from 95% to 19%, p<0.0001), hospitalisation (38% to 2%, p<0.0001) and intensive care (4% to 0, NS). Five patients discontinued omalizumab, two because of an adverse event (anaphylaxis, severe headache, both resolved without sequelae).Omalizumab improved most clinical parameters of Mexican patients with difficult-to-control asthma. Especially the rates of ER visits and hospitalisation were significantly reduced, thus reducing costs. Omalizumab was generally well tolerated.CONCLUSIONOmalizumab improved most clinical parameters of Mexican patients with difficult-to-control asthma. Especially the rates of ER visits and hospitalisation were significantly reduced, thus reducing costs. Omalizumab was generally well tolerated.
Author Gómez Vera, J
Larenas Linnemann, D
del Pozo, M Elena Ramírez
Contreras, E Angélica Contreras
López Tiro, J Jesús
Author_xml – sequence: 1
  givenname: J Jesús
  surname: López Tiro
  fullname: López Tiro, J Jesús
  email: drlopeztiro@gmail.com
  organization: Department of Allergy and Clinical Immunology, H.R. Lic. Adolfo López Mateos, ISSSTE, Mexico City, Mexico. Electronic address: drlopeztiro@gmail.com
– sequence: 2
  givenname: E Angélica Contreras
  surname: Contreras
  fullname: Contreras, E Angélica Contreras
  organization: Department of Allergy and Clinical Immunology, H.R. Lic. Adolfo López Mateos, ISSSTE, Mexico City, Mexico
– sequence: 3
  givenname: M Elena Ramírez
  surname: del Pozo
  fullname: del Pozo, M Elena Ramírez
  organization: Department of Allergy and Clinical Immunology, H.R. Lic. Adolfo López Mateos, ISSSTE, Mexico City, Mexico
– sequence: 4
  givenname: J
  surname: Gómez Vera
  fullname: Gómez Vera, J
  organization: Department of Allergy and Clinical Immunology, H.R. Lic. Adolfo López Mateos, ISSSTE, Mexico City, Mexico
– sequence: 5
  givenname: D
  surname: Larenas Linnemann
  fullname: Larenas Linnemann, D
  organization: Allergy Staff, Hospital Medica Sur, Mexico City, Mexico
BackLink https://www.ncbi.nlm.nih.gov/pubmed/24780091$$D View this record in MEDLINE/PubMed
BookMark eNpNkM1KxDAYRYOMOD_6BIJk6aY1SdukWcrgHwwIom7L1_QLkyFtxiZFxqdXcARX5y4Od3GWZDaEAQm55CznjMubXQ7e45gLxouc85yx-oQseKXqjAupZv_2nCxj3DEmmJDFGZmLUtWMab4g7y8InnpnkcY0dQcaLE3bEZEeEMZIQw_efU09tNQNdA_J4ZAi_XRpSztnrTOTT1kKmQlDGoOnENO2h3NyasFHvDhyRd7u717Xj9nm-eFpfbvJTCV0ylSnW42mZRq05lCUqlBgpCylLgvdgjUFSt1x2ZZYVoVWohLQGVvzCrhAI1bk-vd3P4aPCWNqehcNeg8Dhik2XMqKi6pm6ke9OqpT22PX7EfXw3ho_lqIb0iBZJo
CitedBy_id crossref_primary_10_1016_j_rmed_2017_07_013
crossref_primary_10_3390_jpm12020165
crossref_primary_10_3889_oamjms_2018_1903
crossref_primary_10_1177_1753466619841350
crossref_primary_10_1177_2040622317690494
crossref_primary_10_1016_j_clinthera_2018_05_014
crossref_primary_10_1080_03007995_2018_1505352
crossref_primary_10_4168_aair_2016_8_4_319
crossref_primary_10_1159_000488349
crossref_primary_10_3390_antibiotics12121655
crossref_primary_10_3889_oamjms_2018_394
crossref_primary_10_1007_s41669_019_0117_4
crossref_primary_10_1111_all_13202
crossref_primary_10_2500_aap_2021_42_210014
crossref_primary_10_1016_j_jaip_2017_02_002
crossref_primary_10_1080_1744666X_2019_1574571
crossref_primary_10_1177_1753466618810192
crossref_primary_10_1016_j_waojou_2022_100662
crossref_primary_10_1016_j_waojou_2022_100695
crossref_primary_10_1186_s12890_016_0224_2
crossref_primary_10_1016_j_pupt_2017_03_004
crossref_primary_10_1111_all_12815
crossref_primary_10_1016_j_jaip_2021_01_011
crossref_primary_10_1080_1744666X_2020_1856658
ContentType Journal Article
Copyright Copyright © 2013 SEICAP. Published by Elsevier Espana. All rights reserved.
Copyright_xml – notice: Copyright © 2013 SEICAP. Published by Elsevier Espana. All rights reserved.
DBID CGR
CUY
CVF
ECM
EIF
NPM
7X8
DOI 10.1016/j.aller.2013.11.008
DatabaseName Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
MEDLINE - Academic
DatabaseTitle MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
MEDLINE - Academic
DatabaseTitleList MEDLINE
MEDLINE - Academic
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: 7X8
  name: MEDLINE - Academic
  url: https://search.proquest.com/medline
  sourceTypes: Aggregation Database
DeliveryMethod no_fulltext_linktorsrc
Discipline Medicine
EISSN 1578-1267
ExternalDocumentID 24780091
Genre Journal Article
Observational Study
GeographicLocations Mexico
GeographicLocations_xml – name: Mexico
GroupedDBID ---
.1-
.GJ
0R~
1P~
23M
4.4
457
53G
5GY
7X7
8FI
8FJ
AAAJQ
AACTN
AAEDT
AAEDW
AALRI
AAXUO
ABOCM
ABUWG
ACGFS
ADBBV
ADCUG
AENEX
AEVXI
AFKRA
AFKWA
AFRHN
AFTJW
AIKHN
AITUG
ALIPV
ALMA_UNASSIGNED_HOLDINGS
AMRAJ
ASPBG
AVWKF
AZFZN
BAWUL
BENPR
CCPQU
CGR
CS3
CUY
CVF
DIK
EBS
ECM
EIF
EJD
EMOBN
F5P
FDB
FEDTE
FGOYB
FIRID
FYUFA
HMCUK
HVGLF
HZ~
KOM
NPM
O9-
O9~
OK0
PIMPY
R2-
RIG
SES
SPCBC
UKHRP
Z5R
7X8
EFLBG
ID FETCH-LOGICAL-c529t-7d9b9ecb09a991a34737ac66469439bafc3e69d16b4e45397252adcf815a12ec2
IEDL.DBID 7X8
ISICitedReferencesCount 28
ISICitedReferencesURI http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000352746400002&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
ISSN 1578-1267
IngestDate Fri Sep 05 10:04:40 EDT 2025
Thu Jan 02 22:19:24 EST 2025
IsDoiOpenAccess false
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 2
Keywords Emergency room
Asthmatic crisis
Anti-IgE
Omalizumab
Biological
Difficult-to-control asthma
Severe asthma
Asthma exacerbation
Hospitalisation
Language English
License Copyright © 2013 SEICAP. Published by Elsevier Espana. All rights reserved.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c529t-7d9b9ecb09a991a34737ac66469439bafc3e69d16b4e45397252adcf815a12ec2
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ObjectType-Undefined-3
OpenAccessLink https://doi.org/10.1016/j.aller.2013.11.008
PMID 24780091
PQID 1665125807
PQPubID 23479
ParticipantIDs proquest_miscellaneous_1665125807
pubmed_primary_24780091
PublicationCentury 2000
PublicationDate 2015-03-01
PublicationDateYYYYMMDD 2015-03-01
PublicationDate_xml – month: 03
  year: 2015
  text: 2015-03-01
  day: 01
PublicationDecade 2010
PublicationPlace Spain
PublicationPlace_xml – name: Spain
PublicationTitle Allergologia et immunopathologia
PublicationTitleAlternate Allergol Immunopathol (Madr)
PublicationYear 2015
SSID ssj0020263
Score 2.1789372
Snippet Even though there are multiple options for the treatment of asthma, there still exists a fair group of patients with difficult-to-control asthma. We describe...
SourceID proquest
pubmed
SourceType Aggregation Database
Index Database
StartPage 120
SubjectTerms Adolescent
Adult
Aged
Anti-Asthmatic Agents - therapeutic use
Asthma - drug therapy
Beclomethasone - therapeutic use
Disease Progression
Emergency Medical Services
Female
Humans
Immunoglobulin E - immunology
Male
Mexico
Middle Aged
Omalizumab - therapeutic use
Respiratory Function Tests
Time Factors
Young Adult
Title Real life study of three years omalizumab in patients with difficult-to-control asthma
URI https://www.ncbi.nlm.nih.gov/pubmed/24780091
https://www.proquest.com/docview/1665125807
Volume 43
WOSCitedRecordID wos000352746400002&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText
inHoldings 1
isFullTextHit
isPrint
link http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1JS8QwFA5uiBf3ZdyI4DU6zdqcRETxoIOIytyGbMUBpx1tR9Bf70vb0ZMgeOktUF5e8r635PsQOjaeWWmCIULFNqORlGgmPTGas0wwCPq8fih8o3q9tN_Xd23BrWzHKqd3Yn1R-8LFGvlpIiXEJpF21dn4lUTVqNhdbSU0ZtE8AygTvVr1v7sIkNfXSmqJiJkSlWrKOlTPd0WpkkgImrCTSOPZTX_HmHWsuVr571-uouUWZeLzxi3W0EzI19HibdtH30BP94AP8cswC7jml8VFhivY1YA_wPNLXIwAnn9ORsbiYY5b7tUSx6ItjpIqNWEHqQrSTrpjU1bPI7OJHq8uHy6uSauwQJyguiLKa6uDs11tACcaxhVTxkkJOTMAFWsyx4LUPpGWBy4AulBBjXdZmgiT0ODoFprLizzsICwTb6nlzHuueCS1T3WWqowGTzV1Nu2go6nFBuDBsS1h8lBMysGPzTpouzH7YNxQbQwoV4BodbL7h9V7aAl2UzQDYvtoPoPzGw7QgnuvhuXbYe0a8O3d3X4B-iLDag
linkProvider ProQuest
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Real+life+study+of+three+years+omalizumab+in+patients+with+difficult-to-control+asthma&rft.jtitle=Allergologia+et+immunopathologia&rft.au=L%C3%B3pez+Tiro%2C+J+Jes%C3%BAs&rft.au=Contreras%2C+E+Ang%C3%A9lica+Contreras&rft.au=del+Pozo%2C+M+Elena+Ram%C3%ADrez&rft.au=G%C3%B3mez+Vera%2C+J&rft.date=2015-03-01&rft.eissn=1578-1267&rft.volume=43&rft.issue=2&rft.spage=120&rft_id=info:doi/10.1016%2Fj.aller.2013.11.008&rft_id=info%3Apmid%2F24780091&rft_id=info%3Apmid%2F24780091&rft.externalDocID=24780091
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1578-1267&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1578-1267&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1578-1267&client=summon